Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for AdaptHealth (AHCO) over the last 8 years, with Q3 2025 value amounting to $80.4 million.

  • AdaptHealth's Cash & Equivalents fell 1978.74% to $80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.4 million, marking a year-over-year decrease of 1978.74%. This contributed to the annual value of $109.7 million for FY2024, which is 4228.47% up from last year.
  • Per AdaptHealth's latest filing, its Cash & Equivalents stood at $80.4 million for Q3 2025, which was down 1978.74% from $68.6 million recorded in Q2 2025.
  • In the past 5 years, AdaptHealth's Cash & Equivalents registered a high of $336.7 million during Q3 2021, and its lowest value of $45.1 million during Q2 2023.
  • Over the past 5 years, AdaptHealth's median Cash & Equivalents value was $100.2 million (recorded in 2024), while the average stood at $107.0 million.
  • In the last 5 years, AdaptHealth's Cash & Equivalents soared by 17434.81% in 2021 and then crashed by 6907.51% in 2022.
  • Quarter analysis of 5 years shows AdaptHealth's Cash & Equivalents stood at $149.6 million in 2021, then tumbled by 69.08% to $46.3 million in 2022, then skyrocketed by 66.69% to $77.1 million in 2023, then soared by 42.28% to $109.7 million in 2024, then decreased by 26.78% to $80.4 million in 2025.
  • Its Cash & Equivalents stands at $80.4 million for Q3 2025, versus $68.6 million for Q2 2025 and $53.6 million for Q1 2025.